Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system

Scandinavian Cardiovascular Journal

Volumn 40, Issue 1, 2006, Pages 17-24

  Ekman, Mattias ^a   Sjögren, Iwar ^b   James, Stefan ^c  

^a STOCKHOLM HEALTH ECONOMICS   (Sweden)

^b Falu Lasarett ^*  (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cost effectiveness; Cost utility; Drug eluting stent; Paclitaxel eluting stent; Percutaneous coronary interventions; Restenosis

Indexed keywords

CLOPIDOGREL;

ARTICLE; BUDGET; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECISION MAKING; DRUG ELUTING STENT; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; PRIORITY JOURNAL; REOPERATION; SWEDEN;

CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DRUG DELIVERY SYSTEMS; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; REOPERATION; STENTS; SWEDEN; TAXUS; TICLOPIDINE;

EID: 32144443191     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/14017430500296323     Document Type: Article

References (20)

1. Regar, E and Sianos, G and Serruys, PW. (2001) Stent development and local drug delivery Br Med Bull, 59, pp. 227 - 48.
2. Rajagopal, V and Rockson, SG. (2003) Coronary restenosis: A review of mechanisms and management Am J Med, 115, pp. 547 - 53.
3. Stone, GW and Ellis, SG and Cox, DA and Hermiller, J and O'Shaughnessy, C and Mann, JT and (2004) For the TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med, 350, pp. 221 - 31.
4. Cohen, DJ and Bakhai, A and Shi, C and Githiora, L and Lavelle, T and Berezin, RH and (2004) Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial Circulation, 110, pp. 508 - 14.
5. Stone, GW and Ellis, SG and Cox, DA and Hermiller, J and O'Shaughnessy, C and Mann, JT and (2004) For the TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial Circulation, 109, pp. 1942 - 7.
6. Rihal, CS and Raco, DL and Gersh, BJ and Yusuf, S. (2003) Indications for coronary artery bypass grafts and percutaneous coronary intervention in chronic stable angina Circulation, 108, pp. 2439 - 45.
7. Serruys, PW and Unger, F and Sousa, JE and Jatene, A and Bonnier, HJ and Schonberger, JP and (2001) Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease. The Arterial Revascularization Therapies Study Group N Engl J Med, 344, pp. 1117 - 24.
8. StoneGW. 2-Year Clinical Results of the TAXUS-IV Trial. Transcatheter Cardiovascular Therapeutics (TCT)2004, URL: http://www.tctmd.com/ expert-presentations/multi-slide.html?product_id=7775.
9. MoussaI. Drug-eluting stents in diabetics. Transcatheter Cardiovascular Therapeutics (TCT)2004, URL: http://www.tctmd.com/expert-presentations/ slide.html?type_id=2822.
10. Hill, R and Bagust, A and Bakhai, A and Dickson, R and Dundar, Y and Haycox, A and (2004) Coronary artery stents: A rapid systematic review and economic evaluation Health Technol Assess, 8, pp. iii-iv, 1 - 242.
11. SerruysP. Arterial Revascularization Therapies Study Part II: Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. American College of Cardiology (ACC)2005.
12. NiemelaK. MILESTONE II: A Multi-Center, Global Observational Registry with TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System. TEAM Congress2004.
13. SCAAR Annual report. Annual report of the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)2003[In Swedish].
14. Guyatt, GH and Feeny, DH and Patrick, DL. (1993) Measuring health-related quality of life Ann Intern Med, 118, pp. 622 - 9.
15. Rinfret, S and Grines, CL and Cosgrove, RS and Ho, KK and Cox, DA and Brodie, BR and (2001) Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One-year results from the Stent-PAMI trial J Am Coll Cardiol, 38, pp. 1614 - 21.
16. Hirth, RA and Chernew, ME and Miller, E and Fendrick, AM and Weissert, WG. (2000) Willingness to pay for a quality-adjusted life year: In search of a standard Med Decis Making, 20, pp. 332 - 42.
17. Johannesson, M and Meltzer, D. (1998) Some reflections on cost-effectiveness analysis Health Econ, 7, pp. 1 - 7.
18. Silber, S and Albertsson, P and Aviles, FF and Camici, PG and Colombo, A and Hamm, C and (2005) Guidelines for percutaneous coronary interventions: The task force for percutaneous coronary interventions of the European Society of Cardiology Eur Heart J, 26, pp. 804 - 47.
19. Birch, S and Gafni, A. (2004) The 'NICE' approach to technology assessment: An economics perspective Health Care Manag Sci, 7, pp. 35 - 41.
20. Serruys, PW and van Hout, B and Bonnier, H and Legrand, V and Garcia, E and Macaya, C and (1998) Randomized comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) Lancet, 352, pp. 673 - 81.